BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
August 05 2019 - 1:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today, that the
Company will hold a conference call to update shareholders on
financial results for the second quarter ended June 30, 2019, and
provide a corporate update, at 8:00 a.m, Eastern Daylight Time, on
Tuesday, August 13, 2019.
BrainStorm’s President & CEO, Chaim
Lebovits, will present a corporate update, after which, participant
questions will be answered. Joining Mr. Lebovits to answer
investment community questions will be Ralph Kern, MD, MHSc, Chief
Medical Officer, and Eyal Rubin, Chief Financial Officer.
Participants are encouraged to submit their
questions prior to the call by sending them to:
q@brainstorm-cell.com
Questions should be submitted by 5:00 p.m.
Eastern Daylight Time, Monday, August 12.
The investment community may participate in the
conference call by utilizing the conference ID:
13693394 and dialing the following
numbers:
Toll Free: 1-877-423-9813
Toll/International: 1-201-689-8573
Those interested in listening to the conference
call live via the internet may do so by visiting the “Investors
& Media” page of Brainstorm’s website
at ir.brainstorm-cell.com and clicking on the conference
call link.
A webcast replay of the conference call will be
available for 30 days on the “Investors & Media” page of
Brainstorm’s website.
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671 Replay
Pin Number: 13693394 Replay Start:
Tuesday, August 13, 2019, 11:00 AM ET Replay
Expiry: Tuesday, August 27, 2019, 11:59 PM ET
About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm is
currently conducting a Phase 3 pivotal trial of autologous MSC-NTF
cells for the treatment of amyotrophic lateral sclerosis (ALS).
BrainStorm also recently received U.S. FDA acceptance to initiate a
Phase 2 open-label multicenter trial in progressive MS and
enrollment began in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may," "should," "would,"
"could," "will," "expect," "likely," "believe," "plan," "estimate,"
"predict," "potential," and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
BRAINSTORM CONTACTS: Media: Sean Leous
Westwicke/ICR PR Phone: +1.646.677.1839
Email: sean.leous@icrinc.com
Investors: Michael Levitan Solebury Trout Phone: +1.646.378.2920
Email: mlevitan@soleburytrout.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024